Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LDHA | P00338 | 2/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | EIF4E | P06730 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15608747 | 0.89 | ACHE (0.55) | ACHEKDM4ELDHAHPGDSALDH1A1 | |
| SCHEMBL15609061 | 0.86 | ACHE (0.52) | ACHEKDM4ELDHAHPGDSALDH1A1 | |
| SCHEMBL319326 | 0.85 | PIM1 (0.56) | ACHEKDM4EHPGDSALDH1A1PTGER1 | |
| SCHEMBL26627431 | 0.85 | HTR2B (0.71) | ACHEHTR2BHDAC1HDAC8HDAC6 | |
| SCHEMBL9823334 | 0.83 | HTR2B (0.73) | ACHEKDM4EHPGDSALDH1A1HTR2B | |
| SCHEMBL15608619 | 0.82 | ACHE (0.51) | ACHEKDM4ELDHAHPGDSALDH1A1 | |
| SCHEMBL3542428 | 0.82 | LDHA (0.57) | ACHEKDM4ELDHAHPGDSALDH1A1 | |
| SCHEMBL3536997 | 0.81 | ACHE (0.66) | ACHEKDM4EHPGDSALDH1A1HTR2B | |
| SCHEMBL6183496 | 0.81 | ACHE (0.66) | ACHEKDM4EHPGDSALDH1A1HTR2B | |
| SCHEMBL2545992 | 0.81 | ACHE (0.61) | ACHEKDM4EHPGDSALDH1A1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900657-B1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-03-11 | — | — | EP | disclosed |
| CN-104640858-B | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | 霍夫曼-拉罗奇有限公司 | 2018-11-06 | — | — | CN | disclosed |
| US-9931323-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| CN-103570705-B | Substituted N-((1', 3'-azole-4'-yl)-methyl)-4-benzoyl-hexahydropyridine compound and applications thereof | 中国医学科学院医药生物技术研究所 | 2017-01-25 | — | — | CN | disclosed |
| US-20160213652-A1 | Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use | GENENTECH, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-9328106-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2900657-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| CN-102924445-B | PIM kinase inhibitor, preparation method thereof, and application thereof in pharmacy | SHANGHAI JIKAI MEDICAL TECHNOLOGY CO LTD | 2015-07-08 | — | — | CN | disclosed |
| CN-104640858-A | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2015-05-20 | — | — | CN | disclosed |
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| CN-103570705-A | Substituted N-((1', 3'-azole-4'-yl)-methyl)-4-benzoyl-hexahydropyridine compound and applications thereof | INST MEDICINAL BIOTECHNOLOGY | 2014-02-12 | — | — | CN | disclosed |
| EP-2596790-A1 | Pim kinase inhibitors and methods of their use | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| CN-102924445-A | PIM kinase inhibitor, preparation method thereof, and application thereof in pharmacy | SHANGHAI JIKAI MEDICAL TECHNOLOGY CO LTD | 2013-02-13 | — | — | CN | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | ACHE 4723/4885KDM4E 1409/4885LDHA 643/4885 |
| US-20160213652-A1 | Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use | PIM1, PIM2, PIM3 | ACHE 4812/4885KDM4E 618/4885LDHA 1917/4885 |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ACHE 4723/4885KDM4E 1409/4885LDHA 643/4885 |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | ACHE 4812/4885KDM4E 618/4885LDHA 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.